Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Int Arch Allergy Immunol. 2022 Dec 9;184(3):273–278. doi: 10.1159/000526364

Figure 2. Performance of final ‘ses-IgE+Ara h sIgE’ 5-year prognostic model.

Figure 2.

A. Prognostic epitopes identified at each age (or its combination) for the ‘ses-IgE+Ara h sIgE’ model. B-C. Performance in testing set of the ‘ses-IgE+Ara h sIgE’ model and two ImmunoCAP-based criteria: allergic if PN-sIgE ≥0.35 (“PN-sIgE”) or if PN-sIgE ≥0.35 and Ara h 1 and Ara h 2 and Ara h 3 ≥0.35 kUA/L (“PN-sIgE+Ara h sIgE”).